Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in<i><scp>TP</scp>53</i>

21 Jul 2014

Abstract excerpt

Chronic lymphocytic leukaemia (CLL) is an indolent B-cell malignancy with heterogeneous outcomes. Chromosomal abnormalities in CLL are predictive of the natural disease course; del(11q) and del(17p) are recognized as high risk genetic lesions. Del(17p) is associated with an impaired function of TP53, a key tumour suppressor, and is particularly problematic. Such patients respond poorly to chemo-immunotherapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25040077
DOI: 10.1111/bjh.13042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in<i><scp>TP</scp>53</i>PMID 25040077Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Semantic proximity Read ↗

TP53 aberrations in chronic lymphocytic leukemia.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

[Treatment of Chronic Lymphocytic Leukemia with TP53 Aberrations].Semantic proximity Read ↗

Treatment resistance in chronic lymphocytic leukemia–the role of the p53 pathwaySemantic proximity Read ↗

Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.Semantic proximity Read ↗

Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathwaySemantic proximity Read ↗

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.Semantic proximity Read ↗

Complex TP53 Alterations with del(17p) and del(13q) in Chronic Lymphocytic Leukemia: Clinical Implications from a Case-Based Review.Semantic proximity Read ↗

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read ↗

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.